Previous 10 | Next 10 |
Arcturus Therapeutics (NASDAQ:ARCT) was downgraded to Neutral at Citi with a price target of $29, down from $86, as the firm noted that the path forward for the company's mRNA vaccine ARCT-154 was 'too risky.' On April 20, the company reported data from an ongoing phase 1/2/3 trial ...
The shares of clinical-stage biotech, Arcturus Therapeutics (NASDAQ:ARCT), are trading lower in the morning hours Wednesday as Wall Street reacts to data for the company’s mRNA-based COVID-19 shot, ARCT-154. However, Piper Sandler chose to back the company and explained why the data sh...
Gainers: AlloVir (ALVR) +41%. Biophytis (BPTS) +22%. Clarus Therapeutics (CRXT) +22%. Healthcare Services (HCSG) +20%. BioSig Technologies (BSGM) +6%. Losers: Arcturus Therapeutics (ARCT) -22%. Diffusion Pharmaceuticals (DFFN) -13%. Seer (SEER) -7%. HTG Molecular...
Netflix (NFLX) -27% on Q1 earnings release & as it posts loss of 200,000 subscribers. Arcturus Therapeutics (ARCT) -14% announces 95% overall efficacy for mRNA-based COVID-19 shot. MedAvail Holdings (MDVL) -12%. SunLink Health Systems (SSY) -11%. Roku (ROKU) -7%. Sunsh...
Disclosing topline data from an ongoing Phase 1/2/3 clinical trial, RNA medicines company, Arcturus Therapeutics (NASDAQ:ARCT) said on Wednesday that its self-amplifying mRNA vaccine ARCT-154 showed 95% overall efficacy in the prevention of severe COVID-19 including related deaths. However, t...
95% Efficacy overall for prevention of severe COVID-19 disease including related deaths 55% Efficacy overall for preventing symptomatic COVID-19 disease Study conducted when Delta and Omicron variants were dominant in Vietnam Incidence of unsolicited adverse ev...
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded today at $129.60, eclipsing its 52-week high. So far today approximately 33.7 million shares have been exchanged, as compared to an average 30-day volume of 547,000 shares. Arcturus Therapeutics Holdings Inc. has overhead...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare dise...
COVID-19 vaccine developer Arcturus Therapeutics (ARCT +10.6%) have outperformed rival shot makers on Tuesday after Piper Sandler issued positive remarks on the company’s messenger-RNA-based vaccine booster. Identified as LUNAR-COV19 vaccine candidates, Arcturus has three experimental ...
Gainers: BioNTech (BNTX) +72%. Trip.com Group Limited (TCOM) +25%. StoneCo (STNE) +21%. OraSure Technologies (OSUR) +6%. Brookline Bancorp (BRKL) +5%. Losers: Arcturus Therapeutics Holdings (ARCT) -12%. Embark Technology (EMBK) -9%. CymaBay Therapeutics...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...